Ultrasound contrast agents (UCAs), typically a suspension of gas-filled lipid microspheres (microbubbles), are injected intravenously to improve contrast in suboptimal echocardiograms. There is a general correlation between acoustic signal efficiency, ultrasound frequency, as well as the size and concentration of microbubbles [1] . Because the performance of these products is not directly correlated with the concentration profile of the microsphere gas in the blood, developing and approving a generic UCA product based on traditional pharmacokinetic studies is challenging. To address this challenge, alternative methods are needed to assess the equivalence of generic UCA products based on an understanding of the critical quality attributes with appropriate in vitro tests. Moreover, size distribution of UCA microbubbles need to be noted for safety concerns, for example, microbubbles smaller than 10 µm are preferred to prevent micro pulmonary embolism.
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In our study, cryogenic scanning electron microscopy (cryo-SEM) micrographs was used to visualize and measure the microbubble size with minimal distortion. The cryo-SEM micrograph revealed the hollow structure of a model UCA (approved sulfur hexafluoride lipid microbubbles) that was originally filled with gas ( Figure 1a) , with size distribution ranging from 1 -10 µm, along with a rare presence of microbubbles  10 µm (indicated with an arrow in Figure 1a ). This was further confirmed using quantitative Coulter Counter measurement which reveals 95% (number weighted) of the microbubbles  2 µm and 3 -6 µm-sized microbubbles contributing to 48% of the total bubble volume. When left open to the atmosphere, the concentration of microbubbles decreased by about 22% in the first hour and then was constant for the next four hours (Figure 1b ). This decrease was 14% for small microbubbles (< 2 µm), but 52% for larger microbubbles (> 3 µm), indicating that larger microbubbles are less stable than smaller microbubbles. To investigate the correlation between size distribution of microbubble formulation and acoustic efficacy, the microbubble suspension was fractionated, and each fraction was subsequently characterized for backscattered coefficient at three clinically relevant frequencies (i.e., 2.5 MHz, 5 MHz, and 7 MHz). A linear correlation between the volume concentration of microbubbles and backscattering coefficient was observed at each of the tested frequencies ( Figure 2 ). Findings from this study provide a greater understanding of the critical quality attributes of microbubbles which may be used to support demonstrating the equivalence of a generic UCA product to the reference listed product. 
